{"id":745065,"date":"2015-12-08T08:00:00","date_gmt":"2015-12-08T08:00:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\/"},"modified":"2025-11-07T01:24:43","modified_gmt":"2025-11-07T06:24:43","slug":"findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\/","title":{"rendered":"Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA\u00ae (pembrolizumab) Data"},"content":{"rendered":"<p class=\"bwalignc\">       New Findings Presented at 57th American Society of Hematology Annual        Meeting in Difficult-to-Treat Blood Cancers Including Multiple Myeloma        and Three Types of Lymphoma     <\/p>\n<p class=\"bwalignc\">       Broad KEYTRUDA Development Program in Hematology Includes Four        Registrational Studies     <\/p>\n<p>\n      Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      announced today that new study findings investigating the use of KEYTRUDA<sup>\u00ae<\/sup><br \/>\n      (pembrolizumab), the company\u2019s anti-PD-1 therapy, across a range of<br \/>\n      hematological cancers were presented at the 57<sup>th<\/sup> American<br \/>\n      Society of Hematology (ASH) Annual Meeting. New and updated data were<br \/>\n      presented that demonstrate a potential role for KEYTRUDA in multiple<br \/>\n      myeloma, Hodgkin lymphoma, B-cell lymphoma, and Richter\u2019s transformation<br \/>\n      in chronic lymphocytic leukemia.\n    <\/p>\n<p>\n      \u201cAs part of our commitment to helping people with cancer, Merck is<br \/>\n      leading a broad immuno-oncology clinical program to evaluate the role of<br \/>\n      KEYTRUDA across several types of blood cancer,\u201d said Roger Dansey, M.D.,<br \/>\n      senior vice president and therapeutic area head, oncology late-stage<br \/>\n      development, Merck Research Laboratories. \u201cDespite the numerous advances<br \/>\n      in the treatment of blood cancers, there remains a significant unmet<br \/>\n      medical need. The findings presented at ASH are encouraging, and<br \/>\n      reinforce the potential for KEYTRUDA in the treatment of these types of<br \/>\n      cancer.\u201d\n    <\/p>\n<p>\n      KEYTRUDA data presented at ASH included five presentations, with<br \/>\n      first-time findings in multiple myeloma and updated findings in<br \/>\n      classical Hodgkin lymphoma.\n    <\/p>\n<ul>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #505) Oral Presentation: <\/b><\/i><b>Pembrolizumab in<br \/>\n        Combination with Lenalidomide and Low-Dose Dexamethasone for<br \/>\n        Relapsed\/Refractory Multiple Myeloma (RRMM): Keynote-023. <\/b>J. San<br \/>\n        Miguel. Monday, Dec. 7, 7:00 AM EST. Location: Hall E1 (Orange County<br \/>\n        Convention Center).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #584) Oral Presentation: <\/b><\/i><b>PD-1 Blockade With<br \/>\n        Pembrolizumab in Patients With Classical Hodgkin Lymphoma After<br \/>\n        Brentuximab Vedotin Failure: Safety, Efficacy, and Biomarker<br \/>\n        Assessment. <\/b>P. Armand. Monday, Dec. 7, 10:45 AM EST. Location:<br \/>\n        Hall E2 (Orange County Convention Center).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #506) Oral Presentation:<\/b><\/i> <b>A Phase II Study<br \/>\n        of Anti PD-1 Antibody Pembrolizumab, Pomalidomide and Dexamethasone in<br \/>\n        Patients with Relapsed\/Refractory Multiple Myeloma (RRMM).<\/b> A.<br \/>\n        Badros. Monday, Dec. 7, 7:15 AM EST. Location: Hall E1 (Orange County<br \/>\n        Convention Center).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #834) Oral Presentation:<\/b><\/i> <b>PD-1 Blockade with<br \/>\n        Pembrolizumab (MK-3475) in Relapsed\/Refractory CLL including Richter<br \/>\n        Transformation: an early efficacy report from a phase 2 trial (MC1485).<\/b><br \/>\n        W. Ding. Monday, Dec. 7, 5:45 PM EST. Location: Valencia BC (Orange<br \/>\n        County Convention Center).\n      <\/li>\n<li class=\"bwlistitemmargb\">\n        <i><b>(Abstract #3986) Poster Presentation:<\/b><\/i> <b>Phase 1b Study<br \/>\n        of PD-1 Blockade with Pembrolizumab in Patients with<br \/>\n        Relapsed\/Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL).<\/b><br \/>\n        P. Zinzani. Monday, Dec. 7, 6:00 PM \u2013 8:00 PM EST. Location: Hall A<br \/>\n        (Orange County Convention Center).\n      <\/li>\n<\/ul>\n<p>\n      The KEYTRUDA program currently addresses more than 30 tumor types in<br \/>\n      more than 160 clinical trials, including more than 80 trials that<br \/>\n      combine KEYTRUDA with other cancer treatments. Within this program,<br \/>\n      there is a strong focus on hematological malignancies, with<br \/>\n      approximately 20 trials evaluating KEYTRUDA in blood cancers. This<br \/>\n      includes four registration-enabling studies in Hodgkin lymphoma and<br \/>\n      multiple myeloma, as well as more than 15 combinations of KEYTRUDA with<br \/>\n      other treatments for specific hematologic malignancies.\n    <\/p>\n<p>\n      Registration-enabling trials of KEYTRUDA are also currently enrolling<br \/>\n      patients suffering from melanoma, NSCLC, head and neck cancer, bladder<br \/>\n      cancer, gastric cancer, colorectal cancer, esophageal cancer, and breast<br \/>\n      cancer, with further trials in planning for other malignancies.\n    <\/p>\n<p>\n      <b>About Blood Cancers<\/b>\n    <\/p>\n<p>\n      In most blood cancers, also called hematological malignancies, the<br \/>\n      normal blood cell development process is interrupted by uncontrolled<br \/>\n      growth of an abnormal type of cancerous blood cell. These cancerous<br \/>\n      cells prevent blood from performing many of its functions, like fighting<br \/>\n      off infections or preventing serious bleeding. There are three main<br \/>\n      types of blood cancer: leukemia, lymphoma and myeloma. In 2012, an<br \/>\n      estimated 916,000 people worldwide were diagnosed and 570,000 people<br \/>\n      died from one of the three main types of blood cancer.\n    <\/p>\n<p>\n      <b>About KEYTRUDA (pembrolizumab) Injection 100 mg<\/b>\n    <\/p>\n<p>\n      KEYTRUDA is a humanized monoclonal antibody that works by increasing the<br \/>\n      ability of the body\u2019s immune system to help detect and fight tumor<br \/>\n      cells. KEYTRUDA blocks the interaction between PD-1 and its ligands,<br \/>\n      PD-L1 and PD-L2, thereby activating T lymphocytes which may affect both<br \/>\n      tumor cells and healthy cells.\n    <\/p>\n<p>\n      KEYTRUDA is indicated in the United States at a dose of 2 mg\/kg<br \/>\n      administered as an intravenous infusion over 30 minutes every three<br \/>\n      weeks for the treatment of patients with metastatic non-small cell lung<br \/>\n      cancer (NSCLC) whose tumors express PD-L1 as determined by an<br \/>\n      FDA-approved test with disease progression on or after<br \/>\n      platinum-containing chemotherapy. Patients with EGFR or ALK genomic<br \/>\n      tumor aberrations should have disease progression on FDA-approved<br \/>\n      therapy for these aberrations prior to receiving KEYTRUDA. KEYTRUDA is<br \/>\n      also indicated at the same dosing for the treatment of patients with<br \/>\n      unresectable or metastatic melanoma and disease progression following<br \/>\n      ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. These<br \/>\n      indications are approved under accelerated approval based on tumor<br \/>\n      response rate and durability of response. An improvement in survival or<br \/>\n      disease-related symptoms has not yet been established. Continued<br \/>\n      approval for these indications may be contingent upon verification and<br \/>\n      description of clinical benefit in the confirmatory trials.\n    <\/p>\n<p>\n      <b>Selected Important Safety Information for KEYTRUDA<\/b><sup><b>\u00ae<\/b><\/sup><b><br \/>\n      (pembrolizumab)<\/b>\n    <\/p>\n<p>\n      Pneumonitis, including fatal cases, occurred in patients receiving<br \/>\n      KEYTRUDA. Pneumonitis occurred in 12 (2.9%) of 411 melanoma patients,<br \/>\n      including Grade 2 or 3 cases in 8 (1.9%) and 1 (0.2%) patients,<br \/>\n      respectively, receiving KEYTRUDA. Pneumonitis occurred in 19 (3.5%) of<br \/>\n      550 patients with NSCLC, including Grade 2 (1.1%), 3 (1.3%), 4 (0.4%),<br \/>\n      or 5 (0.2%) pneumonitis in patients, receiving KEYTRUDA. Monitor<br \/>\n      patients for signs and symptoms of pneumonitis. Evaluate suspected<br \/>\n      pneumonitis with radiographic imaging. Administer corticosteroids for<br \/>\n      Grade 2 or greater pneumonitis. Withhold KEYTRUDA for Grade 2;<br \/>\n      permanently discontinue KEYTRUDA for Grade 3 or 4 or recurrent Grade 2<br \/>\n      pneumonitis.\n    <\/p>\n<p>\n      Colitis (including microscopic colitis) occurred in 4 (1%) of 411<br \/>\n      patients with melanoma, including Grade 2 or 3 cases in 1 (0.2%) and 2<br \/>\n      (0.5%) patients, respectively, receiving KEYTRUDA. Colitis occurred in 4<br \/>\n      (0.7 %) of 550 patients with NSCLC, including Grade 2 (0.2%) or 3 (0.4%)<br \/>\n      colitis in patients receiving KEYTRUDA. Monitor patients for signs and<br \/>\n      symptoms of colitis. Administer corticosteroids for Grade 2 or greater<br \/>\n      colitis. Withhold KEYTRUDA for Grade 2 or 3; permanently discontinue<br \/>\n      KEYTRUDA for Grade 4 colitis.\n    <\/p>\n<p>\n      Hepatitis occurred in patients receiving KEYTRUDA. Hepatitis (including<br \/>\n      autoimmune hepatitis) occurred in 2 (0.5%) of 411 patients with<br \/>\n      melanoma, including a Grade 4 case in 1 (0.2%) patient, receiving<br \/>\n      KEYTRUDA. Monitor patients for changes in liver function. Administer<br \/>\n      corticosteroids for Grade 2 or greater hepatitis and, based on severity<br \/>\n      of liver enzyme elevations, withhold or discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Hypophysitis occurred in 2 (0.5%) of 411 patients with melanoma,<br \/>\n      including a Grade 2 case in 1 and a Grade 4 case in 1 (0.2% each)<br \/>\n      patient, receiving KEYTRUDA. Hypophysitis occurred in 1 (0.2 %) of 550<br \/>\n      patients with NSCLC, which was Grade 3 in severity. Monitor patients for<br \/>\n      signs and symptoms of hypophysitis (including hypopituitarism and<br \/>\n      adrenal insufficiency). Administer corticosteroids and hormone<br \/>\n      replacement as indicated. Withhold KEYTRUDA for Grade 2 and withhold or<br \/>\n      discontinue for Grade 3 or Grade 4 hypophysitis.\n    <\/p>\n<p>\n      Hyperthyroidism occurred in 5 (1.2%) of 411 patients with melanoma,<br \/>\n      including Grade 2 or 3 cases in 2 (0.5%) and 1 (0.2%) patients,<br \/>\n      respectively, receiving KEYTRUDA. Hypothyroidism occurred in 34 (8.3%)<br \/>\n      of 411 patients with melanoma, including a Grade 3 case in 1 (0.2%)<br \/>\n      patient, receiving KEYTRUDA. Hyperthyroidism occurred in 10 (1.8%) of<br \/>\n      550 patients with NSCLC, including Grade 2 (0.7%) or 3 (0.3%).<br \/>\n      Hypothyroidism occurred in 38 (6.9%) of 550 patients with NSCLC,<br \/>\n      including Grade 2 (5.5%) or 3 (0.2%). Thyroid disorders can occur at any<br \/>\n      time during treatment. Monitor patients for changes in thyroid function<br \/>\n      (at the start of treatment, periodically during treatment, and as<br \/>\n      indicated based on clinical evaluation) and for clinical signs and<br \/>\n      symptoms of thyroid disorders. Administer replacement hormones for<br \/>\n      hypothyroidism and manage hyperthyroidism with thionamides and<br \/>\n      beta-blockers as appropriate. Withhold or discontinue KEYTRUDA for Grade<br \/>\n      3 or Grade 4 hyperthyroidism.\n    <\/p>\n<p>\n      Type 1 diabetes mellitus, including diabetic ketoacidosis, has occurred<br \/>\n      in patients receiving KEYTRUDA. Monitor patients for hyperglycemia or<br \/>\n      other signs and symptoms of diabetes. Administer insulin for type 1<br \/>\n      diabetes, and withhold KEYTRUDA and administer anti-hyperglycemics in<br \/>\n      patients with severe hyperglycemia.\n    <\/p>\n<p>\n      Nephritis occurred in patients receiving KEYTRUDA. Nephritis occurred in<br \/>\n      3 (0.7%) patients with melanoma, consisting of one case of Grade 2<br \/>\n      autoimmune nephritis (0.2%) and two cases of interstitial nephritis with<br \/>\n      renal failure (0.5%), one Grade 3 and one Grade 4. Monitor patients for<br \/>\n      changes in renal function. Administer corticosteroids for Grade 2 or<br \/>\n      greater nephritis. Withhold KEYTRUDA for Grade 2; permanently<br \/>\n      discontinue KEYTRUDA for Grade 3 or 4 nephritis.\n    <\/p>\n<p>\n      Other clinically important immune-mediated adverse reactions can occur.<br \/>\n      For suspected immune-mediated adverse reactions, ensure adequate<br \/>\n      evaluation to confirm etiology or exclude other causes. Based on the<br \/>\n      severity of the adverse reaction, withhold KEYTRUDA and administer<br \/>\n      corticosteroids. Upon improvement of the adverse reaction to Grade 1 or<br \/>\n      less, initiate corticosteroid taper and continue to taper over at least<br \/>\n      1 month. Resume KEYTRUDA when the adverse reaction remains at Grade 1 or<br \/>\n      less following steroid taper. Permanently discontinue KEYTRUDA for any<br \/>\n      severe or Grade 3 immune-mediated adverse reaction that recurs and for<br \/>\n      any life-threatening immune-mediated adverse reaction.\n    <\/p>\n<p>\n      Across clinical studies with KEYTRUDA, the following clinically<br \/>\n      significant, immune-mediated adverse reactions have occurred: bullous<br \/>\n      pemphigoid and Guillain-Barr\u00e9 syndrome. The following clinically<br \/>\n      significant, immune-mediated adverse reactions occurred in less than 1%<br \/>\n      of patients with melanoma treated with KEYTRUDA: exfoliative dermatitis,<br \/>\n      uveitis, arthritis, myositis, pancreatitis, hemolytic anemia, and<br \/>\n      partial seizures arising in a patient with inflammatory foci in brain<br \/>\n      parenchyma. The following clinically significant, immune-mediated<br \/>\n      adverse reactions occurred in less than 1% of 550 patients with NSCLC<br \/>\n      treated with KEYTRUDA: rash, vasculitis, hemolytic anemia, serum<br \/>\n      sickness, and myasthenia gravis.\n    <\/p>\n<p>\n      Infusion-related reactions, including severe and life-threatening<br \/>\n      reactions, have occurred in patients receiving KEYTRUDA. Monitor<br \/>\n      patients for signs and symptoms of infusion related reactions including<br \/>\n      rigors, chills, wheezing, pruritus, flushing, rash, hypotension,<br \/>\n      hypoxemia, and fever. For severe or life-threatening reactions, stop<br \/>\n      infusion and permanently discontinue KEYTRUDA.\n    <\/p>\n<p>\n      Based on its mechanism of action, KEYTRUDA can cause fetal harm when<br \/>\n      administered to a pregnant woman. If used during pregnancy, or if the<br \/>\n      patient becomes pregnant during treatment, apprise the patient of the<br \/>\n      potential hazard to a fetus. Advise females of reproductive potential to<br \/>\n      use highly effective contraception during treatment and for 4 months<br \/>\n      after the last dose of KEYTRUDA.\n    <\/p>\n<p>\n      Among the 411 patients with metastatic melanoma, KEYTRUDA was<br \/>\n      discontinued for adverse reactions in 9% of 411 patients. Adverse<br \/>\n      reactions, reported in at least two patients, that led to<br \/>\n      discontinuation of KEYTRUDA were: pneumonitis, renal failure, and pain.<br \/>\n      Serious adverse reactions occurred in 36% of patients. The most frequent<br \/>\n      serious adverse reactions, reported in 2% or more of patients, were<br \/>\n      renal failure, dyspnea, pneumonia, and cellulitis. The most common<br \/>\n      adverse reactions (reported in at least 20% of patients) were fatigue<br \/>\n      (47%), cough (30%), nausea (30%), pruritus (30%), rash (29%), decreased<br \/>\n      appetite (26%), constipation (21%), arthralgia (20%), and diarrhea (20%).\n    <\/p>\n<p>\n      Among the 550 patients with metastatic NSCLC, KEYTRUDA was discontinued<br \/>\n      due to adverse reactions in 14% of patients. Serious adverse reactions<br \/>\n      occurred in 38% of patients. The most frequent serious adverse reactions<br \/>\n      reported in 2% or more of patients were pleural effusion, pneumonia,<br \/>\n      dyspnea, pulmonary embolism, and pneumonitis. The most common adverse<br \/>\n      reactions (reported in at least 20% of patients) were fatigue (44%),<br \/>\n      decreased appetite (25%), dyspnea (23%), and cough (29%).\n    <\/p>\n<p>\n      No formal pharmacokinetic drug interaction studies have been conducted<br \/>\n      with KEYTRUDA.\n    <\/p>\n<p>\n      It is not known whether KEYTRUDA is excreted in human milk. Because many<br \/>\n      drugs are excreted in human milk, instruct women to discontinue nursing<br \/>\n      during treatment with KEYTRUDA and for 4 months after the final dose.\n    <\/p>\n<p>\n      Safety and effectiveness of KEYTRUDA have not been established in<br \/>\n      pediatric patients.\n    <\/p>\n<p>\n      <b>Our Focus on Cancer<\/b>\n    <\/p>\n<p>\n      Our goal is to translate breakthrough science into innovative oncology<br \/>\n      medicines to help people with cancer worldwide. At Merck Oncology,<br \/>\n      helping people fight cancer is our passion and supporting accessibility<br \/>\n      to our cancer medicines is our commitment. Our focus is on pursuing<br \/>\n      research in immuno-oncology and we are accelerating every step in the<br \/>\n      journey \u2013 from lab to clinic \u2013 to potentially bring new hope to people<br \/>\n      with cancer. For more information about our oncology clinical trials,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;esheet=51238619&amp;newsitemid=20151208005241&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated%2Fclinicaltrials&amp;index=1&amp;md5=61e5e4b7762e27f7015ad6d39f825b76\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated\/clinicaltrials<\/a>.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      Today&#8217;s Merck is a global health care leader working to help the world<br \/>\n      be well. Merck is known as MSD outside the United States and Canada.<br \/>\n      Through our prescription medicines, vaccines, biologic therapies and<br \/>\n      animal health products, we work with customers and operate in more than<br \/>\n      140 countries to deliver innovative health solutions. We also<br \/>\n      demonstrate our commitment to increasing access to health care through<br \/>\n      far-reaching policies, programs and partnerships. For more information,<br \/>\n      visit <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated&amp;esheet=51238619&amp;newsitemid=20151208005241&amp;lan=en-US&amp;anchor=vip2-msd.com\/merckcom-migrated&amp;index=2&amp;md5=0d7aefcfdd2468f3e79ac65c973cd765\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2FMerck&amp;esheet=51238619&amp;newsitemid=20151208005241&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=f4f6f3b30cc71650048e4d1bbe15cc22\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.facebook.com%2FMerckBeWell&amp;esheet=51238619&amp;newsitemid=20151208005241&amp;lan=en-US&amp;anchor=Facebook&amp;index=4&amp;md5=121e298f593bea0f8836dddf1ed5813a\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.youtube.com%2FMerck&amp;esheet=51238619&amp;newsitemid=20151208005241&amp;lan=en-US&amp;anchor=YouTube&amp;index=5&amp;md5=5ade61cbb09c9a6cc12ad7bd934b9f67\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Fmerck&amp;esheet=51238619&amp;newsitemid=20151208005241&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=6&amp;md5=e421b1cb3c215a71a51dc91d124247cc\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2014 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fwww.sec.gov&amp;esheet=51238619&amp;newsitemid=20151208005241&amp;lan=en-US&amp;anchor=www.sec.gov&amp;index=7&amp;md5=d9bcf7f47da910a541436e39a0d7224c\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for KEYTRUDA (pembrolizumab) at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;esheet=51238619&amp;newsitemid=20151208005241&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_pi.pdf&amp;index=8&amp;md5=f7db71e5df9631fc650935799227222b\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_pi.pdf<\/b><\/a><b><br \/>\n      and Patient Information\/Medication Guide for KEYTRUDA at <\/b><a href=\"http:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;esheet=51238619&amp;newsitemid=20151208005241&amp;lan=en-US&amp;anchor=http%3A%2F%2Fvip2-msd.com\/merckcom-migrated%2Fproduct%2Fusa%2Fpi_circulars%2Fk%2Fkeytruda%2Fkeytruda_mg.pdf&amp;index=9&amp;md5=8cd251f04b5aa9ca69721294f2e35f55\" rel=\"nofollow\"><b>http:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/k\/keytruda\/keytruda_mg.pdf<\/b><\/a><b>.<\/b>\n    <\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20151208005241r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\"><span class=\"bwct31415\"><\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, 267-305-3558<br \/>Kim Hamilton,        908-391-0131<br \/>or<br \/>Investors:<br \/>Teri Loxam, 908-740-1986<br \/>Justin        Holko, 908-740-1879     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>New Findings Presented at 57th American Society of Hematology Annual Meeting in Difficult-to-Treat Blood Cancers Including Multiple Myeloma and Three Types of Lymphoma Broad KEYTRUDA Development Program in Hematology Includes Four Registrational Studies Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new study findings investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, across a range of hematological cancers were presented at the 57 th American Society of Hematology (ASH) Annual Meeting. New and updated data were presented that demonstrate a potential role for KEYTRUDA in multiple myeloma, Hodgkin lymphoma, B-cell lymphoma, and Richter\u2019s transformation in chronic lymphocytic leukemia. \u201cAs part of our commitment to helping people with cancer, Merck is leading a broad immuno-oncology clinical program to evaluate the role of KEYTRUDA across several types of blood cancer,\u201d said Roger Dansey, M.D., senior vice<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,55,289,56],"class_list":["post-745065","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-prescription-medicine-news","tag-press-release","tag-research-and-development-news"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA\u00ae (pembrolizumab) Data - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA\u00ae (pembrolizumab) Data - Merck.com\" \/>\n<meta property=\"og:description\" content=\"New Findings Presented at 57th American Society of Hematology Annual Meeting in Difficult-to-Treat Blood Cancers Including Multiple Myeloma and Three Types of Lymphoma Broad KEYTRUDA Development Program in Hematology Includes Four Registrational Studies Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new study findings investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, across a range of hematological cancers were presented at the 57 th American Society of Hematology (ASH) Annual Meeting. New and updated data were presented that demonstrate a potential role for KEYTRUDA in multiple myeloma, Hodgkin lymphoma, B-cell lymphoma, and Richter\u2019s transformation in chronic lymphocytic leukemia. \u201cAs part of our commitment to helping people with cancer, Merck is leading a broad immuno-oncology clinical program to evaluate the role of KEYTRUDA across several types of blood cancer,\u201d said Roger Dansey, M.D., senior vice\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:24:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"11 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\\\/\",\"name\":\"Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA\u00ae (pembrolizumab) Data - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2015-12-08T08:00:00+00:00\",\"dateModified\":\"2025-11-07T06:24:43+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA\u00ae (pembrolizumab) Data\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA\u00ae (pembrolizumab) Data - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\/","og_locale":"en_US","og_type":"article","og_title":"Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA\u00ae (pembrolizumab) Data - Merck.com","og_description":"New Findings Presented at 57th American Society of Hematology Annual Meeting in Difficult-to-Treat Blood Cancers Including Multiple Myeloma and Three Types of Lymphoma Broad KEYTRUDA Development Program in Hematology Includes Four Registrational Studies Merck (NYSE: MRK), known as MSD outside the United States and Canada, announced today that new study findings investigating the use of KEYTRUDA \u00ae (pembrolizumab), the company\u2019s anti-PD-1 therapy, across a range of hematological cancers were presented at the 57 th American Society of Hematology (ASH) Annual Meeting. New and updated data were presented that demonstrate a potential role for KEYTRUDA in multiple myeloma, Hodgkin lymphoma, B-cell lymphoma, and Richter\u2019s transformation in chronic lymphocytic leukemia. \u201cAs part of our commitment to helping people with cancer, Merck is leading a broad immuno-oncology clinical program to evaluate the role of KEYTRUDA across several types of blood cancer,\u201d said Roger Dansey, M.D., senior vice","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:24:43+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"11 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\/","name":"Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA\u00ae (pembrolizumab) Data - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2015-12-08T08:00:00+00:00","dateModified":"2025-11-07T06:24:43+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/findings-across-a-range-of-hematological-cancers-add-to-the-growing-breadth-of-keytruda-pembrolizumab-data\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Findings Across a Range of Hematological Cancers Add to The Growing Breadth of KEYTRUDA\u00ae (pembrolizumab) Data"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"2dbd8d6c-704c-43bc-9cd4-4ee1caccd7cf","news_item_aria_label":"","media_files":null,"document_path":"https:\/\/s2.q4cdn.com\/584635680\/files\/doc_news\/Findings-Across-a-Range-of-Hematological-Cancers-Add-to-The-Growing-Breadth-of-KEYTRUDA-pembrolizumab-Data-2015.pdf","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745065","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745065\/revisions"}],"predecessor-version":[{"id":3674561,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745065\/revisions\/3674561"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745065"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745065"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}